Reducing CAR-T Manufacturing Costs And Duration Using Next-Generation Cell Therapy Manufacturing Platform

Manufacturing hurdles, including high costs and variability, currently limit patient access to groundbreaking CAR-T cell therapies. Ori Biotech's IRO platform offers a solution, specifically engineered to address these challenges. This poster details how IRO's innovative design, including a bellows-based bioreactor and tubeless sterile connections, improves critical manufacturing steps. The platform achieves higher transduction efficiency, enabling reduced viral vector usage and faster cell expansion to reach target yields.

Discover how these advancements can lead to significant cost-of-goods savings, estimated around 40%. Download the poster to see the full data.